A contrast-enhanced ultrasound-based nomogram for the prediction of therapeutic efficiency of anti-PD-1 plus anti-VEGF agents in advanced hepatocellular carcinoma patients

BACKGROUND: There is no study focusing on noninvasive predictors for the efficacy of sintilimab (anti-PD-1) plus IBI305 (a bevacizumab biosimilar) treatment in advanced hepatocellular carcinoma (HCC). METHOD: A total of 33 patients with advanced HCC were prospectively enrolled and received sintilima...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Chao, Wang, Qian, Hou, Lu, Zhang, Rui, Chen, Yu, Niu, Lijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413126/
https://www.ncbi.nlm.nih.gov/pubmed/37575236
http://dx.doi.org/10.3389/fimmu.2023.1229560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413126/
https://www.ncbi.nlm.nih.gov/pubmed/37575236
http://dx.doi.org/10.3389/fimmu.2023.1229560

Ejemplares similares